ABP-COL-T1 is a preparation of soluble Type 1 Collagen.  It is used for collagen induced aggregation in research of platelet aggregation studies for the evaluation of normal platelet function and is intended for use in inducing platelet aggregation, shape change, and platelet activation.  Platelet response to collagen induction is aggregation and activation.  Collagen is sensitive to the presence of Aspirin®, and similar drugs, at low concentrations.

ABP-COL-T1 is supplied in three separate vials, each containing 950 µg of lyophilized soluble type 1 fibrillar collagen from calf skin.  Prior to reconstitution, the collagen should be brought to room temperature.  When reconstituted with 500 µL of purified water, the stock concentration is 1.9 mg/mL.  Reconstituted collagen is stable for 30 days when stored at 2oC to 8oC.

ADP-COL-T1 leads to platelet activation via the platelet collagen receptor. For suitable platelet activation, the release of endogenous arachidonic acid from the platelet phospholipids is necessary. The arachidonic acid is then transformed to the platelet agonist thromboxane A2 (TXA2) by the enzyme cyclooxygenase. Cyclooxygenase is blocked by Aspirin®. Therefore, ABP-COL-T1 is sensitive to Aspirin® action though not as sensitive as ABP-ARA-1.